[Press release – not published yet] Pfizer announces COVID-19 vaccine in children 5 to 11 years produced strong neutralizing antibody responses.

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years – Pfizer and BioNTech

Commentaries:

Covid-19 vaccine for 5- to 11-year-olds is safe and shows ‘robust’ antibody response, Pfizer says – CNN

Pfizer says COVID-19 vaccine safe, effective in younger children – CIDRAP

Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says – STAT

Expert reaction to press release giving topline results from Pfizer and BioNTech from their phase 2/3 trial looking at safety and antibody responses from their COVID-19 vaccine in children aged 5 to 11 – Science Media Centre

Commentaries on Twitter

I'm so glad to see that Pfizer has data to submit for their vaccine for 5-11 year olds. But any strong assertions about safety, such as for low incidence side-effects like myocarditis, cannot made from a trial of ~1500 children.

— Eric Topol (@EricTopol) September 20, 2021

(thread – click for more)

BREAKING NEWS: Pfizer releases results of 5-11 year old trial for its vaccine. 2-dose 10 microgram regimen (Pfizer uses 30 mcg for 12 and up) administered 21 days apart (sigh, we now know we need longer duration between doses for better effectiveness)https://t.co/43MHnlZgqg

— Monica Gandhi MD, MPH (@MonicaGandhi9) September 20, 2021

(thread – click for more)

BNT-Pfizer vax trial readout (press release) for kids 5-11: it's 2 doses of 10 µg dose – a third of the size of that for 12+. They conclude it had similar results to full dose vax for the 16-25 year age group: minimal data in press release…1/3https://t.co/MgYCmWYhO2

— Hilda Bastian, PhD (@hildabast) September 20, 2021